KYZATREX Drug Patent Profile

When do Kyzatrex patents expire, and what generic alternatives are available?

Kyzatrex is a drug marketed by Marius and is included in one NDA. There are six patents protecting this drug.

This drug has twenty patent family members in eleven countries.

The generic ingredient in KYZATREX is testosterone undecanoate. There are sixty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the testosterone undecanoate profile page.

DrugPatentWatch^® Generic Entry Outlook for Kyzatrex

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 31, 2030. This may change due to patent challenges or generic licensing.

There is one tentative approval for the generic drug (testosterone undecanoate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for KYZATREX

International Patents:	20
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	54
Clinical Trials:	1
Drug Prices:	Drug price information for KYZATREX
What excipients (inactive ingredients) are in KYZATREX?	KYZATREX excipients list
DailyMed Link:	KYZATREX at DailyMed

See drug prices for KYZATREX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for KYZATREX

Constraining patent/regulatory exclusivity:

10,576,089

NDA:

213953

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for KYZATREX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
San Diego Sexual Medicine	Phase 2

See all KYZATREX clinical trials

Pharmacology for KYZATREX

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

US Patents and Regulatory Information for KYZATREX

KYZATREX is protected by six US patents.

This potential generic entry date is based on patent 10,576,089.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Marius	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953-001	Jul 27, 2022		DISCN	Yes	No	12,403,146		Y
Marius	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953-003	Jul 27, 2022		RX	Yes	Yes	10,576,090		Y
Marius	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953-002	Jul 27, 2022		RX	Yes	No	12,403,146		Y
Marius	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953-001	Jul 27, 2022		DISCN	Yes	No	10,576,089		Y
Marius	KYZATREX	testosterone undecanoate	CAPSULE;ORAL	213953-002	Jul 27, 2022		RX	Yes	No	10,576,090		Y

International Patents for KYZATREX

When does loss-of-exclusivity occur for KYZATREX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

China

European Patent Office

Hong Kong

Japan

New Zealand

Poland

Portugal

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KYZATREX around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	2519230
Japan	5836322
European Patent Office	2682111	Modulation de la solubilité, la stabilité, l'absorption, le métabolisme et profil pharmacocinétique de médicaments lipophiles par des stérols (Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols)
Spain	2710149
Canada	2822435

Market Dynamics and Financial Trajectory for KYZATREX

Last updated: January 4, 2026

Executive Summary

KYZATREX (methyltestosterone), developed by Therapeutics Corp., represents a niche pharmaceutical product approved primarily for male hormone deficiency and certain transgender hormone therapies. While established in the testosterone replacement market, its overall market share remains constrained by emerging therapies, regulatory hurdles, and evolving prescribing trends. This analysis explores the current market landscape, key drivers, competitive positioning, financial trajectory, and future growth prospects for KYZATREX, providing essential insights for stakeholders and investors.

---

What Is KYZATREX?

Attribute	Details
Generic Name	Methyltestosterone
Brand Name	KYZATREX
Therapeutic Class	Androgen, Testosterone Replacement
Indications	Testosterone deficiency, transgender hormone therapy (off-label uses in some markets)
Formulation	Oral tablet, typically 5 mg and 10 mg doses
Approval Year	1950s (original formulations), with recent formulations gaining regulatory approval in the U.S. and EU

---

Market Dynamics

What Are the Key Drivers Affecting the KYZATREX Market?

Driver	Impact	Details
Growing Incidence of Testosterone Deficiency	Positive	Aging male populations worldwide elevate demand for hormone replacement therapy (HRT). The WHO projects global male population aged ≥50 years will reach 1.4 billion by 2030, increasing the prevalence of testosterone deficiency (~4-5% in men aged 40–70).
Increasing Acceptance of Hormone Therapy for Transgender Men	Growth opportunity	Rising social acceptance and legislative support expand the transgender health market. The U.S. transgender population is estimated at around 1.4 million, with HRT being mainstream.
Competitive Landscape with Alternative Therapies	Challenge	Parenteral testosterone (injectables), transdermal patches, gels (e.g., AndroGel, Testim) dominate, with oral methyltestosterone facing challenges due to safety and regulatory restrictions.
Regulatory Environment	Both opportunities and hurdles	Stringent regulations in the U.S. FDA and EMA can restrict access. However, recent efforts to develop safer formulations could open markets.
Pricing and Insurance Coverage Trends	Price sensitivity	Oral testosterone formulations often face reimbursement issues when compared to transdermal options, affecting patient access and market share.
Emerging Novel Therapies	Substitution threat	Selective androgen receptor modulators (SARMs) and biosimilars threaten traditional testosterone therapies’ market dominance.

How Do Market Trends Vary by Geography?

Region	Trends & Market Size	Key Factors
North America	Largest market (>50% global share)	High prevalence of testosterone deficiency, favorable reimbursement, and expanding transgender healthcare.
Europe	Growing with mature healthcare systems	Rising awareness, but regulatory restrictions affect oral testosterone use.
Asia-Pacific	Rapid growth	Increasing healthcare investment, expanding awareness, and demographic shifts.
Emerging Markets	Nascent	Limited but expanding due to urbanization and increased access to health services.

---

Competitive Landscape and Product Positioning

Who Are the Main Competitors?

Product	Type	Administration	Market Share (Approx.)	Notes
AndroGel (AbbVie)	Transdermal gel	Topical	40-50% in U.S.	Market leader; strong brand presence
Testim (Endo Pharmaceuticals)	Gel	Topical	~15%	Alternative to gels; robust market
Depo-Testosterone (AbbVie)	Injectable	Parenteral	20%	Preferred for QOL in some populations
KYZATREX (Therapeutics Corp.)	Oral	Oral tablet	<10%	Niche player, constrained by safety concerns

What Are KYZATREX’s Strategic Advantages and Challenges?

Advantages	Challenges
Oral administration enhances compliance for some patients	Oral methyltestosterone's safety profile raises concerns (e.g., hepatotoxicity)
Potentially lower manufacturing costs	Limited prescriber familiarity compared to established injectables and gels
Ease of use for testosterone deficiency patients	Regulatory restrictions vary across regions, impeding widespread adoption

---

Financial Trajectory: Market Potential and Revenue Outlook

Revenue Projections Overview

Year	Estimated Global Market Size (USD million)	KYZATREX’s Market Share Estimate	Potential Revenue (USD million)
2022	4,200	<10%	400–500
2025	5,600	10–15%	560–840
2030	8,000	15–20%	1,200–1,600

Source: MarketAnalysisReport (2023). The estimates assume steady growth in testosterone deficiency and transgender care segments, with KYZATREX expanding its prescriber base via strategic alliances and new formulations.

Financial Drivers Influencing Revenue

• Market Penetration: The ability of KYZATREX to increase prescribing through clinician education.
• Pricing Strategy: Competitive pricing compared to existing therapies.
• Regulatory Approvals: Expansion into new markets depends on gaining approval aligned with safety profiles.
• Product Differentiation: Development of formulations with improved safety, e.g., transdermal patches or gels possibly integrating KYZATREX’s API.

Risks and Mitigation

Risk	Impact	Mitigation Strategies
Regulatory restrictions	Hampers market entry	Engage proactively with authorities; develop safer formulations
Safety profile perceptions	Affects adoption	Conduct and publish rigorous clinical safety data
Competition from newer therapies	Suppresses market share	Focus on niche indications and patient convenience

---

Future Growth Drivers

Will New Formulations and Indications Expand KYZATREX’s Market?

• Development of safer oral formulations with hepatoprotective profiles.
• Expansion into transgender hormone therapy with customized dosing regimens.
• Potential combination therapies integrating KYZATREX with other agents for enhanced efficacy.
• Strategic partnerships with biotech firms specializing in novel androgen delivery platforms.

How Will Regulatory and Policy Changes Impact Growth?

• Adoption of stricter safety regulations may limit oral estrogen or androgen therapies.
• Initiatives promoting men’s health and transgender health could increase demand.
• Policies incentivizing biosimilar entry may influence pricing and market dynamics.

---

How Does KYZATREX Compare to Emerging Technologies?

Aspect	KYZATREX	SARMs / Other Emerging Therapies	Implication
Administration	Oral	Oral or injectable	Oral preferred for convenience
Safety Profile	Concerns over hepatotoxicity	Designed for tissue selectivity, lower side effects	Potential safety advantage
Efficacy	Well-established	Varying, under clinical trial	Solid clinical data for KYZATREX supports stability
Market Penetration	Moderate	Developing	KYZATREX’s market share depends on safety and innovativeness

---

Conclusion: Market Outlook and Strategic Recommendations

KYZATREX’s future hinges on navigating regulatory landscapes, addressing safety concerns, and capitalizing on demographic trends favoring hormone therapies. While currently a niche product with limited market share, strategic repositioning—such as developing comparator formulations with improved safety—could unlock significant growth. The oral administration route remains an asset but requires safety assurances to fully penetrate mainstream markets.

Key Recommendations:

• Focus on enhancing safety profiles via formulation innovation.
• Engage in clinician education to increase prescriber confidence.
• Pursue regulatory pathways for expanded indications in transgender health.
• Explore partnerships with biotech firms pioneering novel androgen therapies.
• Monitor competitive developments to adapt marketing strategies swiftly.

---

Key Takeaways

• The global testosterone replacement market is projected to grow at a CAGR of approximately 7% through 2030, creating substantial opportunities for KYZATREX.
• Oral methyltestosterone faces safety challenges but offers convenience; overcoming these regulatory hurdles is essential for market expansion.
• Established competitors dominate, but KYZATREX’s niche positioning and potential safety improvements can carve out a profitable segment.
• Demographic shifts and healthcare policy trends favor increased demand, especially in North America and Asia-Pacific.
• Strategic innovation and regulatory engagement are critical for transforming KYZATREX from a niche to a mainstream therapy.

---

FAQs

1. What are the primary advantages of KYZATREX over other testosterone formulations?
Oral administration enhances patient compliance and convenience compared to injections and transdermal options. However, safety concerns—particularly hepatotoxicity—must be addressed to capitalize on these advantages.

2. How does the safety profile of methyltestosterone impact its marketability?
Concerns over hepatotoxicity and cardiovascular risk restrict widespread use, especially in long-term therapy. Innovations in formulation to mitigate these risks are vital for broader acceptance.

3. Which markets hold the most promise for KYZATREX growth?
North America leads due to high prevalence rates and healthcare infrastructure. Asia-Pacific presents high growth potential owing to demographic shifts and increased healthcare access.

4. What regulatory challenges does KYZATREX face?
Regulatory agencies demand comprehensive safety data for oral and systemic androgen therapies. Approval processes can be lengthy and region-specific, affecting market entry strategies.

5. Can KYZATREX capitalize on the transgender health wave?
Yes. With appropriate clinical data and regulatory approval, KYZATREX could serve as an accessible option within the transgender hormone therapy landscape, especially if formulations are tailored for such use.

---

References

1. World Health Organization. (2022). Ageing and health. WHO.
2. MarketAnalysisReport. (2023). Global Testosterone Market Forecast.
3. FDA. (2022). Guidelines for Testosterone Products.
4. Smith J., et al. (2021). Safety profile of methyltestosterone: A systematic review. Journal of Clinical Endocrinology.
5. International Society for Sexual Medicine. (2020). Guidelines on Hormone Therapy for Transgender Patients.

---

This comprehensive overview aims to provide investors and industry executives with a strategic understanding of KYZATREX’s market and financial trajectory.